2021 Lavoisier Inc. All rights reservedThis is custom heading element
Lavoisier Polymer Nanoencapsulation PlatformA Novel Polymer Drug Delivery System
Lavoisier’s proprietary polymer nanoencapsulation platform is aimed to address a variety of challenges in the commercialization of biopharmaceuticals, such as therapeutic enzymes, vaccines, and monoclonal antibodies. Endeavors and achievements of applying Lavoisier platform include mitigating undesirable immune responses generated by a given therapeutic biopharmaceutical; enhancing therapeutic effect through controlled delivery of the biopharmaceutical in vivo; and/or stabilizing the biopharmaceutical from manufacturing to administration.
Lavoisier Polymer Nanoencapsulation PlatformA Novel Polymer Drug Delivery System
Lavoisier’s proprietary polymer nanoencapsulation platform is aimed to address a variety of challenges in the commercialization of biopharmaceuticals, such as therapeutic enzymes, vaccines, and monoclonal antibodies. Endeavors and achievements of applying Lavoisier platform include mitigating undesirable immune responses generated by a given therapeutic biopharmaceutical; enhancing therapeutic effect through controlled delivery of the biopharmaceutical in vivo; and/or stabilizing the biopharmaceutical from manufacturing to administration.
Lavoisier Polymer Nanoencapsulation PlatformA Novel Polymer Drug Delivery System
Lavoisier’s proprietary polymer nanoencapsulation platform is aimed to address a variety of challenges in the commercialization of biopharmaceuticals, such as therapeutic enzymes, vaccines, and monoclonal antibodies. Endeavors and achievements of applying Lavoisier platform include mitigating undesirable immune responses generated by a given therapeutic biopharmaceutical; enhancing therapeutic effect through controlled delivery of the biopharmaceutical in vivo; and/or stabilizing the biopharmaceutical from manufacturing to administration.
Lavoisier Polymer Nanoencapsulation PlatformA Novel Polymer Drug Delivery System
Lavoisier’s proprietary polymer nanoencapsulation platform is aimed to address a variety of challenges in the commercialization of biopharmaceuticals, such as therapeutic enzymes, vaccines, and monoclonal antibodies. Endeavors and achievements of applying Lavoisier platform include mitigating undesirable immune responses generated by a given therapeutic biopharmaceutical; enhancing therapeutic effect through controlled delivery of the biopharmaceutical in vivo; and/or stabilizing the biopharmaceutical from manufacturing to administration.
Our core values
Long-Sightedness
ConsultingWP’s thought leadership is evident in our agenda-setting books, white papers, research reports in the business press.
Quality Services
Our professionals see what others don’t, challenge conventional thinking, and consistently deliver innovative solutions.
Integrity Properties
The firm’s 4,000 professionals help clients optimize their businesses, improve their operations and risk profile.
Privacy and Safety
Our capabilities and intellectual capital are enhanced by our deep industry expertise and hands-on, collaborative approach.
Challenging Staff
Institute connects the firm with prominent leaders of the academic community for joint research on frontier issues.
Innovation Solutions
We work side by side with senior executives to accelerate execution through a blend of analytical and management approaches.
Our clients
We are driven to do the best job possible. We pride ourselves on cultivating lasting client relationships built on trust and mutual respect.
Our clients include many of the world’s best-performing and most admired companies, law firms, and industry organizations as well as United States and international regulatory and government agencies.